Nintedanib (BIBF 1120)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Nintedanib (BIBF 1120), covering 2015-01-15 to 2015-01-15. Get the full timeline:
Most recent: Clinical Trial Update: LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer [Phase 3]